SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27969)2/7/1999 4:43:00 PM
From: WTDEC  Read Replies (1) | Respond to of 32384
 
"Here's a recent report (in a peer reviewed journal) indicating that ONTAK (DAB389IL-2) specificity can be improved by pre-treating with IL-1 alpha"

Henry, this seems to be extremely important to a broadened use of Ontak beyond late stage CTCL patients. If I understand Ontak and the report correctly, using IL-1 as a pre-treatment can reduce or possibly eliminate the risk of increased susceptibility to infections since normal lymphocytes and monocytes were sensitive to Ontak when used alone.

Thanks for all the posts today on Ontak's potential uses beyond late stage CTCL. Maybe the Street will wake up to the possibilities...

Regards,

Walter



To: Henry Niman who wrote (27969)2/8/1999 9:44:00 PM
From: LLCF  Read Replies (1) | Respond to of 32384
 
<Here's a recent report (in a peer reviewed journal) indicating that ONTAK (DAB389IL-2) specificity can be improved by pre-treating with IL-1 alpha:>

Would LGND have to do trials to use ONTAK for this purpose???

DAK


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News